

# HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the Ending the  
HIV Epidemic Initiative (*Preliminary Data*):  
National HIV Surveillance System Data Reported  
through September 2022; and Preexposure  
Prophylaxis (PrEP) Data Reported through June 2022**



Centers for Disease  
Control and Prevention  
National Center for HIV,  
Viral Hepatitis, STD, and  
TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through September 2022 and preexposure prophylaxis (PrEP) data reported through June 2022.

*HIV Surveillance Data Tables* is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

### **Suggested citation**

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2022; and preexposure prophylaxis (PrEP) data reported through June 2022. *HIV Surveillance Data Tables* 2022;3(4). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published December 2022. Accessed [date].

**On the Web:** <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

### **Confidential information, referrals, and educational material on HIV infection**

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

### **Acknowledgments**

*HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Weiming Zhu, Dawn Smith, Jianmin Li, Xiaohong Hu, Hao Chang, Pei Hou, Chelsea Walker, Emily Zhu, Lei Yu, Ishwarya Ravichandran, Avery Smithson, Wei Wei, Iddrisu Abdallah, Norma Harris, and Michael Friend (editing and desktop publishing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

<b>Technical Notes</b>	4
<b>References</b>	6
<b>Tables</b>	
1a Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2021 through September 2022—United States (preliminary)	7
1b Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2021 through September 2022—United States and 6 dependent areas (preliminary)	8
1c Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, January 2021 through September 2022—United States and 6 dependent areas (preliminary)	9
1d Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, January 2021 through September 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by selected characteristics, January 2021 through June 2022—45 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2021 through June 2022—45 states and the District of Columbia (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3a Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged $\geq 16$ years, by selected characteristics—United States (preliminary)	20
3b Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged $\geq 16$ years, by area of residence—United States and Puerto Rico (preliminary)	22
3c Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged $\geq 16$ years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	26
4 Ending the HIV Epidemic Phase I jurisdictions	34

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of September 2022 for the years 2021 and 2022, and data on preexposure prophylaxis (PrEP) coverage for the years 2019, 2020, 2021, and 2022 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See *Tabulation and Presentation of Data* for details on how the indicators are calculated.

## TABULATION AND PRESENTATION OF DATA

### Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged  $\geq 13$  years with HIV diagnosed during January 2021 through September 2022 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2015–2019 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/> (*HIV Surveillance Report, 2020*).

### Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged  $\geq 13$  years whose infection was diagnosed during January 2021 through June 2022 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2021 through June 2022 and who had  $\geq 1$  CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2021 through June 2022. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2021 through June 2022 and was reported to NHSS through September 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

### Preexposure Prophylaxis Coverage

Preexposure prophylaxis (PrEP) coverage, reported as a percentage, is defined as the number of persons aged  $\geq 16$  years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged  $\geq 16$  years who had indications for PrEP during the specified year (Tables 3a–c). PrEP coverage is an EHE indicator that is not a

reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

### Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged  $\geq 16$  years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 93% of all prescriptions from retail pharmacies and 77% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2–4]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for  $<40\%$  of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

### Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned

by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [5], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [6]. Because of reliability concerns, subnational estimates of  $<40$  are not included.

### Persons with PrEP indications

U.S. Census Bureau files and their ACS were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [7, 8]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [9].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019–June 2022 by using the IQVIA data reported through June 2022. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019, 2020, 2021, and 2022 PrEP coverage data; consequently, 2019

through June 2022 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [10].

More information on calculating PrEP coverage can be found at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

## REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated July 2, 2022. Accessed November 9, 2022.
2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
4. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
5. U.S. Census Bureau. American Community Survey 5-year data (2009–2020). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>. Published March 2022. Accessed November 9, 2022.
6. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. [https://www.huduser.gov/portal/datasets/usps\\_crosswalk.html](https://www.huduser.gov/portal/datasets/usps_crosswalk.html). Updated August 2022. Accessed November 9, 2022.
7. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
8. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107. doi:10.2174/1874613601206010098
9. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
10. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

**Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through September 2022—United States (preliminary)**

	2021 No.	2022 (January– September) No.
<b>Gender</b>		
Male	28,305	19,097
Female	6,488	4,384
Transgender woman <sup>a</sup>	787	454
Transgender man <sup>a</sup>	58	23
Additional gender identity <sup>b</sup>	42	28
<b>Age at diagnosis (yr)</b>		
13–24	6,854	4,302
25–34	13,114	8,970
35–44	7,585	5,350
45–54	4,418	2,923
≥55	3,709	2,441
<b>Race/ethnicity</b>		
American Indian/Alaska Native	224	129
Asian	736	533
Black/African American	14,424	9,554
Hispanic/Latino <sup>c</sup>	10,307	7,343
Native Hawaiian/other Pacific Islander	76	54
White	8,988	5,988
Multiracial	925	385
<b>Transmission category (based on sex at birth)<sup>d</sup></b>		
Male-to-male sexual contact	23,975	16,419
Injection drug use		
Male	1,414	889
Female	1,070	717
Male-to-male sexual contact and injection drug use	1,356	772
Heterosexual contact <sup>e</sup>		
Male	2,353	1,473
Female	5,426	3,638
Other <sup>f</sup>		
Male	31	25
Female	56	53
<b>Region of residence<sup>g</sup></b>		
Northeast	5,001	3,050
Midwest	4,703	2,980
South	18,919	13,570
West	7,057	4,386
<b>Total</b>	<b>35,680</b>	<b>23,986</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2022. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column totals. Data include transgender and additional gender identity persons.

<sup>e</sup> Sexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>g</sup> Data are based on residence at time of diagnosis of HIV infection.



**Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through September 2022—United States and 6 dependent areas (preliminary)**

	2021 No.	2022 (January– September) No.
<b>Gender</b>		
Male	28,634	19,269
Female	6,566	4,421
Transgender woman <sup>a</sup>	787	454
Transgender man <sup>a</sup>	58	23
Additional gender identity <sup>b</sup>	42	28
<b>Age at diagnosis (yr)</b>		
13–24	6,913	4,327
25–34	13,233	9,048
35–44	7,674	5,393
45–54	4,493	2,957
≥55	3,774	2,470
<b>Race/ethnicity</b>		
American Indian/Alaska Native	224	129
Asian	737	533
Black/African American	14,426	9,555
Hispanic/Latino <sup>c</sup>	10,707	7,547
Native Hawaiian/other Pacific Islander	76	54
White	8,992	5,992
Multiracial	925	385
<b>Transmission category (based on sex at birth)<sup>d</sup></b>		
Male-to-male sexual contact	24,220	16,547
Injection drug use		
Male	1,431	900
Female	1,072	719
Male-to-male sexual contact and injection drug use	1,357	775
Heterosexual contact <sup>e</sup>		
Male	2,417	1,503
Female	5,502	3,672
Other <sup>f</sup>		
Male	31	25
Female	56	54
<b>Region of residence<sup>g</sup></b>		
Northeast	5,001	3,050
Midwest	4,703	2,980
South	18,919	13,570
West	7,057	4,386
U.S. dependent areas	407	209
<b>Total</b>	<b>36,087</b>	<b>24,195</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2022. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column totals. Data include transgender and additional gender identity persons.

<sup>e</sup> Sexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>g</sup> Data are based on residence at time of diagnosis of HIV infection.



**Table 1c. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by area of residence, January 2021 through September 2022—United States and 6 dependent areas (preliminary)**

Area of residence	2021	2022
	No.	(January–September) No.
Alabama	507	248
Alaska	30	16
Arizona	785	608
Arkansas	341	238
California	4,246	2,408
Colorado	408	296
Connecticut	231	121
Delaware	80	83
District of Columbia	193	122
Florida	4,556	4,106
Georgia	2,181	1,611
Hawaii	64	34
Idaho	55	22
Illinois	1,083	651
Indiana	528	406
Iowa	124	74
Kansas	154	93
Kentucky	392	271
Louisiana	932	682
Maine	30	26
Maryland	760	516
Massachusetts	436	185
Michigan	634	446
Minnesota	298	177
Mississippi	422	253
Missouri	548	350
Montana	22	6
Nebraska	104	61
Nevada	500	363
New Hampshire	32	22
New Jersey	1,153	709
New Mexico	147	30
New York	2,125	1,354
North Carolina	1,389	987
North Dakota	37	1
Ohio	909	512
Oklahoma	383	179
Oregon	199	183
Pennsylvania	913	595
Rhode Island	68	35
South Carolina	663	425
South Dakota	30	23
Tennessee	831	575
Texas	4,349	2,595
Utah	133	41
Vermont	13	3
Virginia	792	582
Washington	461	370
West Virginia	148	97
Wisconsin	254	186
Wyoming	7	9
<b>Subtotal</b>	<b>35,680</b>	<b>23,986</b>
<b>U.S. dependent areas</b>		
American Samoa	0	0
Guam	0	0
Northern Mariana Islands	0	0
Puerto Rico	402	207
Republic of Palau	0	0
U.S. Virgin Islands	5	2
<b>Subtotal</b>	<b>407</b>	<b>209</b>
<b>Total</b>	<b>36,087</b>	<b>24,195</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2022. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 1d. Diagnoses of HIV infection among persons aged  $\geq$  13 years, by area of residence, January 2021 through September 2022—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)**

Area of residence	2021 No.	2022 (January– September) No.
<b>Arizona</b>		
Maricopa County	520	419
<b>California</b>		
Alameda County	186	132
Los Angeles County	1,422	732
Orange County	266	165
Riverside County	249	176
Sacramento County	170	86
San Bernardino County	299	130
San Diego County	317	15
San Francisco County	187	148
<b>District of Columbia</b>	193	122
<b>Florida</b>		
Broward County	647	570
Duval County	288	202
Hillsborough County	312	285
Miami-Dade County	1,196	1,206
Orange County	442	317
Palm Beach County	299	277
Pinellas County	126	108
<b>Georgia</b>		
Cobb County	148	104
DeKalb County	315	243
Fulton County	507	405
Gwinnett County	142	96
<b>Illinois</b>		
Cook County	771	426
<b>Indiana</b>		
Marion County	216	166
<b>Louisiana</b>		
East Baton Rouge Parish	148	92
Orleans Parish	146	101
<b>Maryland</b>		
Baltimore City	159	108
Montgomery County	100	76
Prince George's County	231	157
<b>Massachusetts</b>		
Suffolk County	128	53
<b>Michigan</b>		
Wayne County	252	180
<b>Nevada</b>		
Clark County	445	331
<b>New Jersey</b>		
Essex County	265	157
Hudson County	159	115

**Table 1d. Diagnoses of HIV infection among persons aged  $\geq$  13 years, by area of residence, January 2021 through September 2022—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	2021 No.	2022 (January– September) No.
<b>New York</b>		
Bronx County	419	245
Kings County	440	279
New York County	323	226
Queens County	337	207
<b>North Carolina</b>		
Mecklenburg County	277	187
<b>Ohio</b>		
Cuyahoga County	165	73
Franklin County	187	102
Hamilton County	123	63
<b>Pennsylvania</b>		
Philadelphia County	359	226
<b>Puerto Rico</b>		
San Juan Municipio	99	66
<b>Tennessee</b>		
Shelby County	294	231
<b>Texas</b>		
Bexar County	332	192
Dallas County	797	552
Harris County	1,153	797
Tarrant County	306	212
Travis County	228	160
<b>Washington</b>		
King County	220	207

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on residence at diagnosis of HIV infection.

Data are for cases reported to CDC through September 2022.

Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2021 through June 2022—45 states and the District of Columbia (preliminary)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2021</b>				
<b>Gender</b>					
Male	26,355	21,729	82.4	4,626	17.6
Female	5,954	4,894	82.2	1,060	17.8
Transgender woman <sup>a</sup>	751	632	84.2	119	15.8
Transgender man <sup>a</sup>	56	52	92.9	4	7.1
Additional gender identity <sup>b</sup>	38	32	84.2	6	15.8
<b>Age at diagnosis (yr)</b>					
13–24	6,430	5,176	80.5	1,254	19.5
25–34	12,208	10,061	82.4	2,147	17.6
35–44	7,021	5,814	82.8	1,207	17.2
45–54	4,067	3,410	83.8	657	16.2
≥55	3,428	2,878	84.0	550	16.0
<b>Race/ethnicity</b>					
American Indian/Alaska Native	221	183	82.8	38	17.2
Asian	696	611	87.8	85	12.2
Black/African American	13,415	10,735	80.0	2,680	20.0
Hispanic/Latino <sup>c</sup>	9,633	8,230	85.4	1,403	14.6
Native Hawaiian/other Pacific Islander	74	60	81.1	14	18.9
White	8,275	6,835	82.6	1,440	17.4
Multiracial	840	685	81.5	155	18.5
<b>Transmission category (based on sex at birth)<sup>d</sup></b>					
Male-to-male sexual contact	22,515	18,711	83.1	3,804	16.9
Injection drug use	2,218	1,696	76.5	522	23.5
Male	1,252	943	75.3	309	24.7
Female	966	753	77.9	214	22.1
Male-to-male sexual contact and injection drug use	1,256	997	79.4	259	20.6
Heterosexual contact <sup>e</sup>	7,085	5,870	82.8	1,215	17.2
Male	2,088	1,715	82.1	373	17.9
Female	4,997	4,155	83.1	842	16.9
<b>Total<sup>f</sup></b>	<b>33,154</b>	<b>27,339</b>	<b>82.5</b>	<b>5,815</b>	<b>17.5</b>

**Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2021 through June 2022—45 states and the District of Columbia (preliminary) (cont)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2022 (January–June)</b>					
<b>Gender</b>					
Male	13,164	10,820	82.2	2,344	17.8
Female	3,041	2,455	80.7	586	19.3
Transgender woman <sup>a</sup>	344	293	85.2	51	14.8
Transgender man <sup>a</sup>	16	15	93.8	1	6.3
Additional gender identity <sup>b</sup>	18	17	94.4	1	5.6
<b>Age at diagnosis (yr)</b>					
13–24	3,062	2,438	79.6	624	20.4
25–34	6,170	5,058	82.0	1,112	18.0
35–44	3,673	3,062	83.4	611	16.6
45–54	2,023	1,671	82.6	352	17.4
≥55	1,655	1,371	82.8	284	17.2
<b>Race/ethnicity</b>					
American Indian/Alaska Native	95	73	76.8	22	23.2
Asian	368	331	89.9	37	10.1
Black/African American	6,516	5,110	78.4	1,406	21.6
Hispanic/Latino <sup>c</sup>	5,148	4,414	85.7	734	14.3
Native Hawaiian/other Pacific Islander	45	37	82.2	8	17.8
White	4,124	3,389	82.2	735	17.8
Multiracial	287	246	85.7	41	14.3
<b>Transmission category (based on sex at birth)<sup>d</sup></b>					
Male-to-male sexual contact	11,366	9,394	82.6	1,972	17.4
Injection drug use	1,082	839	77.6	242	22.4
Male	583	446	76.6	136	23.4
Female	499	393	78.7	106	21.3
Male-to-male sexual contact and injection drug use	551	450	81.7	101	18.3
Heterosexual contact <sup>e</sup>	3,530	2,871	81.3	659	18.7
Male	1,008	825	81.8	184	18.2
Female	2,521	2,046	81.2	475	18.8
<b>Total<sup>f</sup></b>	<b>16,583</b>	<b>13,600</b>	<b>82.0</b>	<b>2,983</b>	<b>18.0</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

*Note.* Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through June 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column totals. Data include transgender and additional gender identity persons.

<sup>e</sup> Sexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through June 2022—45 states and the District of Columbia (preliminary)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
		<b>2021</b>			
Alabama	507	387	76.3	120	23.7
Alaska	30	28	93.3	2	6.7
Arizona	785	664	84.6	121	15.4
Arkansas	341	263	77.1	78	22.9
California	4,246	3,542	83.4	704	16.6
Colorado	408	341	83.6	67	16.4
Connecticut	231	204	88.3	27	11.7
Delaware	80	68	85.0	12	15.0
District of Columbia	193	155	80.3	38	19.7
Florida	4,556	3,839	84.3	717	15.7
Georgia	2,181	1,807	82.9	374	17.1
Hawaii	64	54	84.4	10	15.6
Illinois	1,083	927	85.6	156	14.4
Indiana	528	403	76.3	125	23.7
Iowa	124	106	85.5	18	14.5
Kansas	154	139	90.3	15	9.7
Louisiana	932	751	80.6	181	19.4
Maine	30	26	86.7	4	13.3
Maryland	760	660	86.8	100	13.2
Massachusetts	436	400	91.7	36	8.3
Michigan	634	549	86.6	85	13.4
Minnesota	298	245	82.2	53	17.8
Mississippi	422	297	70.4	125	29.6
Missouri	548	427	77.9	121	22.1
Montana	22	20	90.9	2	9.1
Nebraska	104	88	84.6	16	15.4
Nevada	500	436	87.2	64	12.8
New Hampshire	32	32	100	0	0.0
New Mexico	147	126	85.7	21	14.3
New York	2,125	1,833	86.3	292	13.7
North Carolina	1,389	1,115	80.3	274	19.7
North Dakota	37	31	83.8	6	16.2
Ohio	909	759	83.5	150	16.5
Oklahoma	383	302	78.9	81	21.1
Oregon	199	157	78.9	42	21.1
Rhode Island	68	52	76.5	16	23.5
South Carolina	663	564	85.1	99	14.9
South Dakota	30	25	83.3	5	16.7
Tennessee	831	583	70.2	248	29.8
Texas	4,349	3,446	79.2	903	20.8
Utah	133	111	83.5	22	16.5
Virginia	792	632	79.8	160	20.2
Washington	461	405	87.9	56	12.1
West Virginia	148	107	72.3	41	27.7
Wisconsin	254	227	89.4	27	10.6
Wyoming	7	6	85.7	1	14.3
<b>Total</b>	<b>33,154</b>	<b>27,339</b>	<b>82.5</b>	<b>5,815</b>	<b>17.5</b>

**Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through June 2022—45 states and the District of Columbia (preliminary) (cont)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2022 (January–June)</b>				
Alabama	195	85	43.6	110	56.4
Alaska	12	10	83.3	2	16.7
Arizona	455	380	83.5	75	16.5
Arkansas	138	102	73.9	36	26.1
California	1,879	1,583	84.2	296	15.8
Colorado	225	185	82.2	40	17.8
Connecticut	101	83	82.2	18	17.8
Delaware	56	49	87.5	7	12.5
District of Columbia	102	85	83.3	17	16.7
Florida	2,907	2,535	87.2	372	12.8
Georgia	1,156	977	84.5	179	15.5
Hawaii	30	26	86.7	4	13.3
Illinois	540	460	85.2	80	14.8
Indiana	302	236	78.1	66	21.9
Iowa	53	50	94.3	3	5.7
Kansas	66	60	90.9	6	9.1
Louisiana	484	390	80.6	94	19.4
Maine	16	16	100	0	0.0
Maryland	383	347	90.6	36	9.4
Massachusetts	163	143	87.7	20	12.3
Michigan	308	272	88.3	36	11.7
Minnesota	125	102	81.6	23	18.4
Mississippi	173	78	45.1	95	54.9
Missouri	246	202	82.1	44	17.9
Montana	6	4	66.7	2	33.3
Nebraska	48	42	87.5	6	12.5
Nevada	247	222	89.9	25	10.1
New Hampshire	12	8	66.7	4	33.3
New Mexico	27	23	85.2	4	14.8
New York	1,037	913	88.0	124	12.0
North Carolina	680	564	82.9	116	17.1
North Dakota	1	0	0.0	1	100
Ohio	440	374	85.0	66	15.0
Oklahoma	125	95	76.0	30	24.0
Oregon	136	113	83.1	23	16.9
Rhode Island	28	28	100	0	0.0
South Carolina	349	243	69.6	106	30.4
South Dakota	18	13	72.2	5	27.8
Tennessee	406	295	72.7	111	27.3
Texas	1,985	1,441	72.6	544	27.4
Utah	30	27	90.0	3	10.0
Virginia	422	348	82.5	74	17.5
Washington	258	228	88.4	30	11.6
West Virginia	79	46	58.2	33	41.8
Wisconsin	129	113	87.6	16	12.4
Wyoming	5	4	80.0	1	20.0
<b>Total</b>	<b>16,583</b>	<b>13,600</b>	<b>82.0</b>	<b>2,983</b>	<b>18.0</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

*Note.* Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through June 2022 and reported to NHSS through September 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.



**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2021</b>				
<b>Arizona</b>					
Maricopa County	520	448	86.2	72	13.8
<b>California</b>					
Alameda County	186	166	89.2	20	10.8
Los Angeles County	1,422	1,168	82.1	254	17.9
Orange County	266	231	86.8	35	13.2
Riverside County	249	193	77.5	56	22.5
Sacramento County	170	148	87.1	22	12.9
San Bernardino County	299	229	76.6	70	23.4
San Diego County	317	267	84.2	50	15.8
San Francisco County	187	177	94.7	10	5.3
<b>District of Columbia</b>	193	155	80.3	38	19.7
<b>Florida</b>					
Broward County	647	543	83.9	104	16.1
Duval County	288	230	79.9	58	20.1
Hillsborough County	312	254	81.4	58	18.6
Miami-Dade County	1,196	1,025	85.7	171	14.3
Orange County	442	366	82.8	76	17.2
Palm Beach County	299	253	84.6	46	15.4
Pinellas County	126	103	81.7	23	18.3
<b>Georgia</b>					
Cobb County	148	127	85.8	21	14.2
DeKalb County	315	270	85.7	45	14.3
Fulton County	507	425	83.8	82	16.2
Gwinnett County	142	128	90.1	14	9.9
<b>Illinois</b>					
Cook County	771	665	86.3	106	13.7
<b>Indiana</b>					
Marion County	216	171	79.2	45	20.8
<b>Louisiana</b>					
East Baton Rouge Parish	148	117	79.1	31	20.9
Orleans Parish	146	132	90.4	14	9.6
<b>Maryland</b>					
Baltimore City	159	136	85.5	23	14.5
Montgomery County	100	88	88.0	12	12.0
Prince George's County	231	200	86.6	31	13.4
<b>Massachusetts</b>					
Suffolk County	128	123	96.1	5	3.9
<b>Michigan</b>					
Wayne County	252	213	84.5	39	15.5
<b>Nevada</b>					
Clark County	445	385	86.5	60	13.5
<b>New York</b>					
Bronx County	419	364	86.9	55	13.1
Kings County	440	378	85.9	62	14.1
New York County	323	268	83.0	55	17.0
Queens County	337	289	85.8	48	14.2

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged  $\geq 13$  years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	Total diagnoses	$\geq 1$ CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2021 (<i>cont</i>)</b>				
<b>North Carolina</b>					
Mecklenburg County	277	226	81.6	51	18.4
<b>Ohio</b>					
Cuyahoga County	165	147	89.1	18	10.9
Franklin County	187	162	86.6	25	13.4
Hamilton County	123	110	89.4	13	10.6
<b>Pennsylvania</b>					
Philadelphia County	359	300	83.6	59	16.4
<b>Tennessee</b>					
Shelby County	294	177	60.2	117	39.8
<b>Texas</b>					
Bexar County	332	267	80.4	65	19.6
Dallas County	797	617	77.4	180	22.6
Harris County	1,153	874	75.8	279	24.2
Tarrant County	306	239	78.1	67	21.9
Travis County	228	197	86.4	31	13.6
<b>Washington</b>					
King County	220	195	88.6	25	11.4

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2022 (January–June)</b>				
<b>Arizona</b>					
Maricopa County	301	257	85.4	44	14.6
<b>California</b>					
Alameda County	84	72	85.7	12	14.3
Los Angeles County	595	492	82.7	103	17.3
Orange County	112	92	82.1	20	17.9
Riverside County	144	111	77.1	33	22.9
Sacramento County	74	67	90.5	7	9.5
San Bernardino County	111	82	73.9	29	26.1
San Diego County	13	10	76.9	3	23.1
San Francisco County	114	107	93.9	7	6.1
<b>District of Columbia</b>	102	85	83.3	17	16.7
<b>Florida</b>					
Broward County	407	359	88.2	48	11.8
Duval County	140	106	75.7	34	24.3
Hillsborough County	188	163	86.7	25	13.3
Miami-Dade County	834	743	89.1	91	10.9
Orange County	273	238	87.2	35	12.8
Palm Beach County	185	163	88.1	22	11.9
Pinellas County	75	62	82.7	13	17.3
<b>Georgia</b>					
Cobb County	79	69	87.3	10	12.7
DeKalb County	175	145	82.9	30	17.1
Fulton County	272	240	88.2	32	11.8
Gwinnett County	75	65	86.7	10	13.3
<b>Illinois</b>					
Cook County	364	309	84.9	55	15.1
<b>Indiana</b>					
Marion County	117	93	79.5	24	20.5
<b>Louisiana</b>					
East Baton Rouge Parish	69	55	79.7	14	20.3
Orleans Parish	72	63	87.5	9	12.5
<b>Maryland</b>					
Baltimore City	85	79	92.9	6	7.1
Montgomery County	58	54	93.1	4	6.9
Prince George's County	110	100	90.9	10	9.1
<b>Massachusetts</b>					
Suffolk County	44	40	90.9	4	9.1
<b>Michigan</b>					
Wayne County	125	107	85.6	18	14.4
<b>Nevada</b>					
Clark County	220	198	90.0	22	10.0
<b>New York</b>					
Bronx County	190	160	84.2	30	15.8
Kings County	213	194	91.1	19	8.9
New York County	187	159	85.0	28	15.0
Queens County	159	141	88.7	18	11.3

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2021 through June 2022—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2022 (January–June) (<i>cont</i>)</b>					
<b>North Carolina</b>					
Mecklenburg County	132	104	78.8	28	21.2
<b>Ohio</b>					
Cuyahoga County	59	53	89.8	6	10.2
Franklin County	92	82	89.1	10	10.9
Hamilton County	51	45	88.2	6	11.8
<b>Pennsylvania</b>					
Philadelphia County	175	141	80.6	34	19.4
<b>Tennessee</b>					
Shelby County	160	102	63.7	58	36.3
<b>Texas</b>					
Bexar County	170	121	71.2	49	28.8
Dallas County	417	290	69.5	127	30.5
Harris County	577	406	70.4	171	29.6
Tarrant County	172	115	66.9	57	33.1
Travis County	117	96	82.1	21	17.9
<b>Washington</b>					
King County	138	122	88.4	16	11.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

*Note.* Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through September 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through June 2022 and reported to NHSS through September 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by selected characteristics—United States (preliminary)**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2019</b>			
<b>Sex at birth</b>			
Male	253,974	989,200	25.7
Female	21,065	227,010	9.3
<b>Age (yr)</b>			
16–24	37,628	246,290	15.3
25–34	111,733	434,680	25.7
35–44	64,091	238,470	26.9
45–54	37,437	173,420	21.6
≥55	24,202	123,350	19.6
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	37,590	468,540	8.0
Hispanic/Latino <sup>e</sup>	45,069	312,820	14.4
Other	12,285	131,180	9.4
White	180,239	300,650	59.9
<b>Total</b>	<b>275,182</b>	<b>1,216,210</b>	<b>22.6</b>
<b>2020 (COVID-19 pandemic)</b>			
<b>Sex at birth</b>			
Male	277,229	989,200	28.0
Female	23,591	227,010	10.4
<b>Age (yr)</b>			
16–24	37,741	246,290	15.3
25–34	120,343	434,680	27.7
35–44	71,916	238,470	30.2
45–54	40,504	173,420	23.4
≥55	30,280	123,350	24.5
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	43,609	468,540	9.3
Hispanic/Latino <sup>e</sup>	51,047	312,820	16.3
Other	12,811	131,180	9.8
White	193,420	300,650	64.3
<b>Total</b>	<b>300,887</b>	<b>1,216,210</b>	<b>24.7</b>
<b>2021</b>			
<b>Sex at birth</b>			
Male	338,121	989,200	34.2
Female	28,052	227,010	12.4
<b>Age (yr)</b>			
16–24	48,602	246,290	19.7
25–34	145,912	434,680	33.6
35–44	88,631	238,470	37.2
45–54	46,290	173,420	26.7
≥55	36,841	123,350	29.9
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	52,091	468,540	11.1
Hispanic/Latino <sup>e</sup>	63,991	312,820	20.5
Other	15,802	131,180	12.0
White	234,573	300,650	78.0
<b>Total</b>	<b>366,458</b>	<b>1,216,210</b>	<b>30.1</b>

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by selected characteristics—United States (preliminary) (cont)**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2022 (January–June)</b>			
<b>Sex at birth</b>			
Male	297,888	989,200	30.1
Female	20,441	227,010	9.0
<b>Age (yr)</b>			
16–24	35,032	246,290	14.2
25–34	124,681	434,680	28.7
35–44	82,388	238,470	34.5
45–54	41,227	173,420	23.8
≥55	34,945	123,350	28.3
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	42,374	468,540	9.0
Hispanic/Latino <sup>e</sup>	54,674	312,820	17.5
Other	13,955	131,180	10.6
White	207,397	300,650	69.0
<b>Total</b>	<b>318,400</b>	<b>1,216,210</b>	<b>26.2</b>

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through June 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

<sup>e</sup> Hispanic/Latino persons can be of any race.

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019</b>		
Alabama	1,835	11,020	16.7
Alaska	227	1,780	12.8
Arizona	4,578	25,780	17.8
Arkansas	728	5,130	14.2
California	41,585	165,030	25.2
Colorado	4,393	25,120	17.5
Connecticut	2,665	9,560	27.9
Delaware	479	4,400	10.9
District of Columbia	5,891	12,950	45.5
Florida	21,759	125,330	17.4
Georgia	8,651	39,030	22.2
Hawaii	818	4,360	18.8
Idaho	476	4,790	9.9
Illinois	16,654	55,860	29.8
Indiana	2,984	22,170	13.5
Iowa	1,414	4,760	29.7
Kansas	906	5,060	17.9
Kentucky	1,602	12,990	12.3
Louisiana	3,917	15,920	24.6
Maine	652	3,950	16.5
Maryland	4,924	27,300	18.0
Massachusetts	9,312	24,900	37.4
Michigan	4,357	29,570	14.7
Minnesota	4,212	21,720	19.4
Mississippi	950	4,530	21.0
Missouri	3,477	18,370	18.9
Montana	269	2,290	11.7
Nebraska	618	2,180	28.3
Nevada	2,185	11,390	19.2
New Hampshire	618	3,020	20.5
New Jersey	5,676	25,280	22.5
New Mexico	1,071	6,800	15.8
New York	35,300	72,640	48.6
North Carolina	5,398	32,490	16.6
North Dakota	189	1,520	12.4
Ohio	6,125	40,320	15.2
Oklahoma	1,158	11,030	10.5
Oregon	3,397	19,750	17.2
Pennsylvania	10,105	36,490	27.7
Puerto Rico	330	9,700	3.4
Rhode Island	1,076	3,880	27.7
South Carolina	1,726	10,390	16.6
South Dakota	151	910	16.6
Tennessee	3,896	22,460	17.3
Texas	23,127	123,790	18.7
Utah	2,042	6,840	29.9
Vermont	336	1,060	31.7
Virginia	4,410	31,430	14.0
Washington	9,891	40,050	24.7
West Virginia	568	5,250	10.8
Wisconsin	2,466	12,980	19.0
Wyoming	96	890	10.8



**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2020 (COVID-19 pandemic)</b>			
Alabama	1,909	11,020	17.3
Alaska	243	1,780	13.7
Arizona	5,055	25,780	19.6
Arkansas	864	5,130	16.8
California	42,256	165,030	25.6
Colorado	4,793	25,120	19.1
Connecticut	2,471	9,560	25.8
Delaware	480	4,400	10.9
District of Columbia	5,979	12,950	46.2
Florida	34,539	125,330	27.6
Georgia	9,767	39,030	25.0
Hawaii	906	4,360	20.8
Idaho	664	4,790	13.9
Illinois	15,973	55,860	28.6
Indiana	3,201	22,170	14.4
Iowa	1,550	4,760	32.6
Kansas	950	5,060	18.8
Kentucky	1,658	12,990	12.8
Louisiana	3,565	15,920	22.4
Maine	671	3,950	17.0
Maryland	4,797	27,300	17.6
Massachusetts	9,379	24,900	37.7
Michigan	4,673	29,570	15.8
Minnesota	4,222	21,720	19.4
Mississippi	1,095	4,530	24.2
Missouri	3,565	18,370	19.4
Montana	296	2,290	12.9
Nebraska	718	2,180	32.9
Nevada	2,501	11,390	22.0
New Hampshire	647	3,020	21.4
New Jersey	5,914	25,280	23.4
New Mexico	1,233	6,800	18.1
New York	34,150	72,640	47.0
North Carolina	6,159	32,490	19.0
North Dakota	184	1,520	12.1
Ohio	6,835	40,320	17.0
Oklahoma	1,525	11,030	13.8
Oregon	3,827	19,750	19.4
Pennsylvania	10,573	36,490	29.0
Puerto Rico	368	9,700	3.8
Rhode Island	1,150	3,880	29.6
South Carolina	2,110	10,390	20.3
South Dakota	143	910	15.7
Tennessee	5,168	22,460	23.0
Texas	27,515	123,790	22.2
Utah	2,375	6,840	34.7
Vermont	321	1,060	30.3
Virginia	5,126	31,430	16.3
Washington	10,062	40,050	25.1
West Virginia	522	5,250	9.9
Wisconsin	2,526	12,980	19.5
Wyoming	99	890	11.1

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021</b>		
Alabama	2,764	11,020	25.1
Alaska	307	1,780	17.2
Arizona	6,578	25,780	25.5
Arkansas	1,278	5,130	24.9
California	50,292	165,030	30.5
Colorado	6,182	25,120	24.6
Connecticut	3,048	9,560	31.9
Delaware	648	4,400	14.7
District of Columbia	6,805	12,950	52.5
Florida	42,618	125,330	34.0
Georgia	12,186	39,030	31.2
Hawaii	1,138	4,360	26.1
Idaho	875	4,790	18.3
Illinois	18,406	55,860	33.0
Indiana	4,267	22,170	19.2
Iowa	1,952	4,760	41.0
Kansas	1,276	5,060	25.2
Kentucky	2,230	12,990	17.2
Louisiana	4,152	15,920	26.1
Maine	908	3,950	23.0
Maryland	5,793	27,300	21.2
Massachusetts	10,176	24,900	40.9
Michigan	5,914	29,570	20.0
Minnesota	5,275	21,720	24.3
Mississippi	1,599	4,530	35.3
Missouri	4,171	18,370	22.7
Montana	396	2,290	17.3
Nebraska	1,004	2,180	46.1
Nevada	4,879	11,390	42.8
New Hampshire	800	3,020	26.5
New Jersey	7,279	25,280	28.8
New Mexico	1,597	6,800	23.5
New York	39,133	72,640	53.9
North Carolina	7,975	32,490	24.5
North Dakota	248	1,520	16.3
Ohio	8,497	40,320	21.1
Oklahoma	2,327	11,030	21.1
Oregon	4,695	19,750	23.8
Pennsylvania	13,065	36,490	35.8
Puerto Rico	607	9,700	6.3
Rhode Island	1,514	3,880	39.0
South Carolina	2,947	10,390	28.4
South Dakota	214	910	23.5
Tennessee	7,239	22,460	32.2
Texas	34,772	123,790	28.1
Utah	3,279	6,840	47.9
Vermont	482	1,060	45.5
Virginia	6,290	31,430	20.0
Washington	11,385	40,050	28.4
West Virginia	708	5,250	13.5
Wisconsin	2,819	12,980	21.7
Wyoming	141	890	15.8

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2022 (January–June)</b>		
Alabama	2,548	11,020	23.1
Alaska	271	1,780	15.2
Arizona	6,122	25,780	23.7
Arkansas	1,185	5,130	23.1
California	44,961	165,030	27.2
Colorado	5,375	25,120	21.4
Connecticut	2,859	9,560	29.9
Delaware	628	4,400	14.3
District of Columbia	6,065	12,950	46.8
Florida	32,084	125,330	25.6
Georgia	10,437	39,030	26.7
Hawaii	1,104	4,360	25.3
Idaho	781	4,790	16.3
Illinois	16,723	55,860	29.9
Indiana	3,974	22,170	17.9
Iowa	1,616	4,760	33.9
Kansas	1,124	5,060	22.2
Kentucky	2,080	12,990	16.0
Louisiana	3,390	15,920	21.3
Maine	797	3,950	20.2
Maryland	4,988	27,300	18.3
Massachusetts	9,463	24,900	38.0
Michigan	5,164	29,570	17.5
Minnesota	4,859	21,720	22.4
Mississippi	1,254	4,530	27.7
Missouri	3,726	18,370	20.3
Montana	347	2,290	15.2
Nebraska	928	2,180	42.6
Nevada	3,015	11,390	26.5
New Hampshire	738	3,020	24.4
New Jersey	6,375	25,280	25.2
New Mexico	1,426	6,800	21.0
New York	34,238	72,640	47.1
North Carolina	7,187	32,490	22.1
North Dakota	248	1,520	16.3
Ohio	7,660	40,320	19.0
Oklahoma	2,045	11,030	18.5
Oregon	4,359	19,750	22.1
Pennsylvania	11,776	36,490	32.3
Puerto Rico	524	9,700	5.4
Rhode Island	1,384	3,880	35.7
South Carolina	2,562	10,390	24.7
South Dakota	199	910	21.9
Tennessee	6,491	22,460	28.9
Texas	30,201	123,790	24.4
Utah	2,966	6,840	43.4
Vermont	431	1,060	40.7
Virginia	5,517	31,430	17.6
Washington	10,275	40,050	25.7
West Virginia	644	5,250	12.3
Wisconsin	2,411	12,980	18.6
Wyoming	127	890	14.3

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through June 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019</b>		
<b>Arizona</b>			
Maricopa County	3,538	22,720	15.6
<b>California</b>			
Alameda County	2,160	8,930	24.2
Los Angeles County	13,677	67,450	20.3
Orange County	2,039	10,510	19.4
Riverside County	1,793	11,080	16.2
Sacramento County	951	5,920	16.1
San Bernardino County	753	11,890	6.3
San Diego County	3,731	14,500	25.7
San Francisco County	8,833	10,840	81.5
<b>District of Columbia</b>	5,891	12,950	45.5
<b>Florida</b>			
Broward County	3,837	20,470	18.7
Duval County	498	8,970	5.6
Hillsborough County	1,376	12,910	10.7
Miami-Dade County	6,484	21,760	29.8
Orange County	2,777	15,310	18.1
Palm Beach County	883	9,170	9.6
Pinellas County	1,132	9,530	11.9
<b>Georgia</b>			
Cobb County	566	3,070	18.4
DeKalb County	1,542	6,290	24.5
Fulton County	3,309	13,120	25.2
Gwinnett County	681	3,240	21.0
<b>Illinois</b>			
Cook County	13,625	39,060	34.9
<b>Indiana</b>			
Marion County	1,151	9,150	12.6
<b>Louisiana</b>			
East Baton Rouge Parish	491	1,810	27.1
Orleans Parish	1,508	4,590	32.9
<b>Maryland</b>			
Baltimore City	898	6,330	14.2
Montgomery County	891	5,770	15.4
Prince George's County	800	4,040	19.8
<b>Massachusetts</b>			
Suffolk County	2,767	6,520	42.4
<b>Michigan</b>			
Wayne County	1,205	9,270	13.0
<b>Nevada</b>			
Clark County	1,866	11,670	16.0
<b>New Jersey</b>			
Essex County	676	4,090	16.5
Hudson County	1,060	4,650	22.8

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019 (cont)</b>		
<b>New York</b>			
Bronx County	2,203	5,570	39.6
Kings County	7,571	15,650	48.4
New York County	14,158	15,540	91.1
Queens County	3,852	9,230	41.7
<b>North Carolina</b>			
Mecklenburg County	1,339	8,450	15.8
<b>Ohio</b>			
Cuyahoga County	959	7,520	12.8
Franklin County	2,035	11,620	17.5
Hamilton County	568	7,720	7.4
<b>Pennsylvania</b>			
Philadelphia County	3,638	9,840	37.0
<b>Puerto Rico</b>			
San Juan Municipio <sup>d</sup>	— <sup>d</sup>	2,190	n/a
<b>Tennessee</b>			
Shelby County	633	6,450	9.8
<b>Texas</b>			
Bexar County	1,527	11,920	12.8
Dallas County	4,093	28,670	14.3
Harris County	4,935	40,670	12.1
Tarrant County	1,457	11,340	12.8
Travis County	4,529	11,590	39.1
<b>Washington</b>			
King County	6,898	17,890	38.6

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2020 (COVID-19 pandemic)</b>		
<b>Arizona</b>			
Maricopa County	3,894	22,720	17.1
<b>California</b>			
Alameda County	2,021	8,930	22.6
Los Angeles County	14,707	67,450	21.8
Orange County	2,196	10,510	20.9
Riverside County	1,933	11,080	17.4
Sacramento County	974	5,920	16.5
San Bernardino County	819	11,890	6.9
San Diego County	3,796	14,500	26.2
San Francisco County	8,128	10,840	75.0
<b>District of Columbia</b>	5,979	12,950	46.2
<b>Florida</b>			
Broward County	6,795	20,470	33.2
Duval County	723	8,970	8.1
Hillsborough County	1,526	12,910	11.8
Miami-Dade County	10,207	21,760	46.9
Orange County	3,884	15,310	25.4
Palm Beach County	3,014	9,170	32.9
Pinellas County	1,219	9,530	12.8
<b>Georgia</b>			
Cobb County	654	3,070	21.3
DeKalb County	1,685	6,290	26.8
Fulton County	3,607	13,120	27.5
Gwinnett County	792	3,240	24.4
<b>Illinois</b>			
Cook County	12,889	39,060	33.0
<b>Indiana</b>			
Marion County	1,207	9,150	13.2
<b>Louisiana</b>			
East Baton Rouge Parish	530	1,810	29.3
Orleans Parish	1,326	4,590	28.9
<b>Maryland</b>			
Baltimore City	842	6,330	13.3
Montgomery County	898	5,770	15.6
Prince George's County	821	4,040	20.3
<b>Massachusetts</b>			
Suffolk County	2,805	6,520	43.0
<b>Michigan</b>			
Wayne County	1,231	9,270	13.3
<b>Nevada</b>			
Clark County	2,099	11,670	18.0
<b>New Jersey</b>			
Essex County	709	4,090	17.3
Hudson County	1,065	4,650	22.9

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2020 (COVID-19 pandemic) (cont)</b>			
<b>New York</b>			
Bronx County	2,019	5,570	36.2
Kings County	7,441	15,650	47.5
New York County	13,761	15,540	88.6
Queens County	3,788	9,230	41.0
<b>North Carolina</b>			
Mecklenburg County	1,573	8,450	18.6
<b>Ohio</b>			
Cuyahoga County	973	7,520	12.9
Franklin County	2,310	11,620	19.9
Hamilton County	637	7,720	8.3
<b>Pennsylvania</b>			
Philadelphia County	3,489	9,840	35.5
<b>Puerto Rico</b>			
San Juan Municipio <sup>d</sup>	— <sup>d</sup>	2,190	n/a
<b>Tennessee</b>			
Shelby County	813	6,450	12.6
<b>Texas</b>			
Bexar County	1,781	11,920	14.9
Dallas County	5,154	28,670	18.0
Harris County	5,979	40,670	14.7
Tarrant County	1,642	11,340	14.5
Travis County	5,045	11,590	43.5
<b>Washington</b>			
King County	6,967	17,890	38.9



**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021</b>		
<b>Arizona</b>			
Maricopa County	5,039	22,720	22.2
<b>California</b>			
Alameda County	2,219	8,930	24.8
Los Angeles County	18,470	67,450	27.4
Orange County	2,831	10,510	26.9
Riverside County	2,547	11,080	23.0
Sacramento County	1,099	5,920	18.6
San Bernardino County	1,194	11,890	10.0
San Diego County	4,435	14,500	30.6
San Francisco County	8,178	10,840	75.4
<b>District of Columbia</b>	6,805	12,950	52.5
<b>Florida</b>			
Broward County	8,341	20,470	40.7
Duval County	882	8,970	9.8
Hillsborough County	2,022	12,910	15.7
Miami-Dade County	11,436	21,760	52.6
Orange County	4,721	15,310	30.8
Palm Beach County	2,770	9,170	30.2
Pinellas County	1,647	9,530	17.3
<b>Georgia</b>			
Cobb County	810	3,070	26.4
DeKalb County	2,016	6,290	32.1
Fulton County	4,275	13,120	32.6
Gwinnett County	1,000	3,240	30.9
<b>Illinois</b>			
Cook County	14,746	39,060	37.8
<b>Indiana</b>			
Marion County	1,589	9,150	17.4
<b>Louisiana</b>			
East Baton Rouge Parish	585	1,810	32.3
Orleans Parish	1,518	4,590	33.1
<b>Maryland</b>			
Baltimore City	974	6,330	15.4
Montgomery County	1,146	5,770	19.9
Prince George's County	988	4,040	24.5
<b>Massachusetts</b>			
Suffolk County	2,812	6,520	43.1
<b>Michigan</b>			
Wayne County	1,553	9,270	16.8
<b>Nevada</b>			
Clark County	4,285	11,670	36.7
<b>New Jersey</b>			
Essex County	841	4,090	20.6
Hudson County	1,301	4,650	28.0

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021 (cont)</b>		
<b>New York</b>			
Bronx County	2,078	5,570	37.3
Kings County	8,877	15,650	56.7
New York County	15,783	15,540	101.6
Queens County	4,272	9,230	46.3
<b>North Carolina</b>			
Mecklenburg County	1,965	8,450	23.3
<b>Ohio</b>			
Cuyahoga County	1,267	7,520	16.8
Franklin County	2,747	11,620	23.6
Hamilton County	816	7,720	10.6
<b>Pennsylvania</b>			
Philadelphia County	4,036	9,840	41.0
<b>Puerto Rico</b>			
San Juan Municipio	62	2,190	2.8
<b>Tennessee</b>			
Shelby County	942	6,450	14.6
<b>Texas</b>			
Bexar County	2,355	11,920	19.8
Dallas County	6,544	28,670	22.8
Harris County	7,494	40,670	18.4
Tarrant County	2,110	11,340	18.6
Travis County	5,789	11,590	49.9
<b>Washington</b>			
King County	7,641	17,890	42.7

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2022 (January–June)</b>			
<b>Arizona</b>			
Maricopa County	4,742	22,720	20.9
<b>California</b>			
Alameda County	1,951	8,930	21.8
Los Angeles County	17,049	67,450	25.3
Orange County	2,438	10,510	23.2
Riverside County	2,350	11,080	21.2
Sacramento County	976	5,920	16.5
San Bernardino County	1,094	11,890	9.2
San Diego County	3,894	14,500	26.9
San Francisco County	7,057	10,840	65.1
<b>District of Columbia</b>	6,065	12,950	46.8
<b>Florida</b>			
Broward County	5,984	20,470	29.2
Duval County	793	8,970	8.8
Hillsborough County	1,829	12,910	14.2
Miami-Dade County	7,618	21,760	35.0
Orange County	4,011	15,310	26.2
Palm Beach County	1,637	9,170	17.9
Pinellas County	1,572	9,530	16.5
<b>Georgia</b>			
Cobb County	703	3,070	22.9
DeKalb County	1,739	6,290	27.6
Fulton County	3,679	13,120	28.0
Gwinnett County	869	3,240	26.8
<b>Illinois</b>			
Cook County	13,375	39,060	34.2
<b>Indiana</b>			
Marion County	1,513	9,150	16.5
<b>Louisiana</b>			
East Baton Rouge Parish	450	1,810	24.9
Orleans Parish	1,221	4,590	26.6
<b>Maryland</b>			
Baltimore City	825	6,330	13.0
Montgomery County	1,044	5,770	18.1
Prince George's County	801	4,040	19.8
<b>Massachusetts</b>			
Suffolk County	2,642	6,520	40.5
<b>Michigan</b>			
Wayne County	1,312	9,270	14.2
<b>Nevada</b>			
Clark County	2,456	11,670	21.0
<b>New Jersey</b>			
Essex County	718	4,090	17.6
Hudson County	1,176	4,650	25.3

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2022, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2022 (January–June) (cont)</b>			
<b>New York</b>			
Bronx County	1,532	5,570	27.5
Kings County	7,711	15,650	49.3
New York County	14,031	15,540	90.3
Queens County	3,762	9,230	40.8
<b>North Carolina</b>			
Mecklenburg County	1,725	8,450	20.4
<b>Ohio</b>			
Cuyahoga County	1,166	7,520	15.5
Franklin County	2,447	11,620	21.1
Hamilton County	720	7,720	9.3
<b>Pennsylvania</b>			
Philadelphia County	3,604	9,840	36.6
<b>Puerto Rico</b>			
San Juan Municipio	70	2,190	3.2
<b>Tennessee</b>			
Shelby County	815	6,450	12.6
<b>Texas</b>			
Bexar County	2,084	11,920	17.5
Dallas County	5,551	28,670	19.4
Harris County	6,461	40,670	15.9
Tarrant County	1,822	11,340	16.1
Travis County	5,120	11,590	44.2
<b>Washington</b>			
King County	6,901	17,890	38.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through June 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Data value <40 was not reported due to unreliability.

**Table 4. Ending the HIV Epidemic Phase I jurisdictions**

<b>Counties</b>	<b>Territories</b>	<b>States</b>
<b>Arizona</b>	<b>Puerto Rico<sup>a</sup></b>	Alabama
Maricopa County	San Juan Municipio <sup>a</sup>	Arkansas
<b>California</b>		Kentucky <sup>a</sup>
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
<b>District of Columbia</b>		
<b>Florida</b>		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
<b>Georgia</b>		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
<b>Illinois</b>		
Cook County		
<b>Indiana</b>		
Marion County		
<b>Louisiana</b>		
East Baton Rouge Parish		
Orleans Parish		
<b>Maryland</b>		
Baltimore City		
Montgomery County		
Prince George's County		
<b>Massachusetts</b>		
Suffolk County		
<b>Michigan</b>		
Wayne County		
<b>Nevada</b>		
Clark County		
<b>New Jersey<sup>a</sup></b>		
Essex County <sup>a</sup>		
Hudson County <sup>a</sup>		
<b>New York</b>		
Bronx County		
Kings County		
New York County		
Queens County		

**Table 4. Ending the HIV Epidemic Phase I jurisdictions (cont)**

Counties	Territories	States
<b>North Carolina</b>		
Mecklenburg County		
<b>Ohio</b>		
Cuyahoga County		
Franklin County		
Hamilton County		
<b>Pennsylvania<sup>a</sup></b>		
Philadelphia County		
<b>Tennessee</b>		
Shelby County		
<b>Texas</b>		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
<b>Washington</b>		
King County		

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only]; PrEP, preexposure prophylaxis [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

<sup>a</sup> Linkage to care data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: Kentucky, New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.